RxDoctor Payments Data

Anil Yadav, MD

Internal Medicine · Jasper, GANPI 1245323468

Payments from drug & device makers

$11,018in general payments, 2019–2025

Across 670 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$768
  • Sanofi-aventis U.S. LLC$689
  • Johnson & Johnson$575
  • GSK$517
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$10,975100%
  • Education$170%
  • Entertainment$130%
  • Other$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,018 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$312,122
Medicare patients
793
Services billed
6,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide98$117,237
OzempicSemaglutide71$111,506
EliquisApixaban32$27,831
ShingrixVaricella-Zoster Ge/As01b/Pf116$25,872
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,530
FarxigaDapagliflozin Propanediol15$14,988
Soliqua 100-33Insulin Glargine/Lixisenatide11$12,281
Repatha SureclickEvolocumab12$8,697
EdarbiAzilsartan Medoxomil15$3,116
SynthroidLevothyroxine Sodium27$2,743
Boostrix TdapDiphth,pertuss(Acell),tet Vac36$2,533
Esomeprazole Magnesium47$1,504
Levothyroxine Sodium173$1,469
Rosuvastatin Calcium101$1,314
Gabapentin71$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$468$117,23798 claims
Novo NordiskOzempic$2,412$111,50671 claims
GSKShingrix, Trelegy Ellipta$517$46,401140 claims
PfizerEliquis$267$27,83132 claims
AstraZenecaFarxiga$768$14,98815 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$689$12,28111 claims
Arbor Pharmaceuticals, Inc.Edarbi$70$3,11615 claims
AbbVieSynthroid$2,079$2,74327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Jasper

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →